News & Updates

Show Multimedia Only

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

The oral selective tyrosine kinase inhibitor sunvozertinib demonstrates therapeutic potential in patients with nonsmall cell lung cancer (NSCLC) with EGFR exon 20 insertions (exon20ins) who have previously received platinum-based chemotherapy, according to the results of a phase II WU-KONG6 study.

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

Nocturnal reflux, snoring linked to increased risk of asthma, respiratory problems

22 Dec 2023

People with nocturnal gastroesophageal reflux (GER) and habitual snoring are vulnerable to developing asthma and respiratory symptoms, according to a study.

Nocturnal reflux, snoring linked to increased risk of asthma, respiratory problems

22 Dec 2023

Mobocertinib only as good as platinum chemo in first-line NSCLC treatment

20 Dec 2023 by

In the first-line treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) patients with EGFR exon 20 insertion (ex20ins) mutations, the investigational mobocertinib is safe and efficacious but not necessarily better than platinum-based chemotherapy, according to the phase III EXCLAIM-2 trial.

Mobocertinib only as good as platinum chemo in first-line NSCLC treatment

20 Dec 2023

Product Highlight - Aviar

19 Dec 2023

Tiotropium Br DPI (pre-metered dose) 18 mcg

Product Highlight - Aviar

19 Dec 2023

Product Highlight - EXTUSIV

19 Dec 2023

Levodropropizine Syrup 30 mg/5 mL

Product Highlight - EXTUSIV

19 Dec 2023

Product Highlight - TRELEGY ELLIPTA

19 Dec 2023

Fluticasone furoate, umeclidinium Br, vilanterol trifenatate dry powd for inhalation 100 mcg/62.5 mcg/25 mcg

Product Highlight - TRELEGY ELLIPTA

19 Dec 2023

Getting both COVID-19 and flu shots at once just as effective as separate vaccinations

15 Dec 2023 by

Coadministration of the BNT162b2 BA.4/5 bivalent mRNA COVID-19 vaccine (BNT162b2-biv) and the seasonal influenza vaccine (SIV) offers protection against the two infections, with an efficacy that is similar as when giving each vaccine alone, according to a study.